MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584863 | Name: Nosantine

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Nosantine is an immunomodulating compound related to inosine in structure and isoprinosine in action that enhances T-cell dependent immune responses.

Chemical Structure

Nosantine
Nosantine
CAS#76600-30-1

Theoretical Analysis

MedKoo Cat#: 584863

Name: Nosantine

CAS#: 76600-30-1

Chemical Formula: C14H22N4O2

Exact Mass: 278.1743

Molecular Weight: 278.36

Elemental Analysis: C, 60.41; H, 7.97; N, 20.13; O, 11.50

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Nosantine; NPT 15392
IUPAC/Chemical Name
6H-Purin-6-one, 1,9-dihydro-9-(1-(1-hydroxyethyl)heptyl)-, (R*,S*)-
InChi Key
RSMDQPNZAPMDJC-MNOVXSKESA-N
InChi Code
InChI=1S/C14H22N4O2/c1-3-4-5-6-7-11(10(2)19)18-9-17-12-13(18)15-8-16-14(12)20/h8-11,19H,3-7H2,1-2H3,(H,15,16,20)/t10-,11+/m1/s1
SMILES Code
O=C1NC=NC2=C1N=CN2[C@H]([C@H](O)C)CCCCCC
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 278.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Coffey RG, Hartley L, Polson JB, Krzanowski JJ, Hadden JW. Selective inhibition by NPT 15392 of lymphocyte cyclic GMP phosphodiesterase. Biochem Pharmacol. 1984 Nov 1;33(21):3411-7. PubMed PMID: 6093811. 2: Exon JH, Henningsen GM, Koller LD, Talcott PA. The selectivity of isoprinosine, NPT 15392, avridine and cyclophosphamide on multiple immune responses in rats. Int J Immunopharmacol. 1986;8(1):53-62. PubMed PMID: 2420733. 3: Hadden JW, Hadden EM, Spira T, Settineri R, Simon L, Giner-Sorolla A. Effects of NPT 15392 in vitro on human leukocyte functions. Int J Immunopharmacol. 1982;4(3):235-42. PubMed PMID: 6179891. 4: Donnelly RP, Tsang KY, Bishop LR, Fudenberg HH. Kinetic analysis of the immunopotentiating effect of the hypoxanthine analogue, NPT-15392, on the interleukin-2 production potential of human lymphocytes. Int J Immunopharmacol. 1986;8(6):621-7. PubMed PMID: 3491799. 5: Jones C, Lee C, Hoehler F, Koyama P, Skinner W, Lamott JA. Observations on the immunomodulator NPT 15392 in New Zealand Black mice. Int J Immunopharmacol. 1983;5(1):85-90. PubMed PMID: 6840935. 6: Florentin I, Taylor E, Davigny M, Mathé G, Hadden JW. Kinetic studies of the immunopharmacologic effects of NPT 15392 in mice. Int J Immunopharmacol. 1982;4(3):225-33. PubMed PMID: 6213574. 7: Wiranowska-Stewart M, Hadden JW. Effects of isoprinosine and NPT 15392 on interleukin-2 (IL-2) production. Int J Immunopharmacol. 1986;8(1):63-9. PubMed PMID: 2420734. 8: Simon LN, Hoehler FK, McKenzie DT, Hadden JW. Isoprinosine and NPT 15392: immunomodulation and cancer. Adv Exp Med Biol. 1983;166:241-59. PubMed PMID: 6196956. 9: Ikehara S, Hadden JW, Good RA, Lunzer DG, Pahwa RN. In vitro effects of two immunopotentiators, Isoprinosine and NPT 15392, on murine T-cell differentiation and function. Thymus. 1981 Aug;3(2):87-95. PubMed PMID: 6170135. 10: Merluzzi VJ, Walker MM, Williams N, Susskind B, Hadden JW, Faanes RB. Immunoenhancing activity of NPT 15392: a potential immune response modifier. Int J Immunopharmacol. 1982;4(3):219-24. PubMed PMID: 7049973. 11: De Simone C, Cilli A, Zanzoglu S, Pugnaloni L, De Santis S, Sorice F. The effect of NPT 15392, 9-(erythro-2-hydroxy-3-nonyl)-6-hydroxypurine, on the phytohemagglutinin of OKT3+, OKT4+, OKT8+, and OKM1+ cell-depleted and undepleted peripheral blood mononuclear cells. Clin Immunol Immunopathol. 1984 Nov;33(2):191-8. PubMed PMID: 6488589. 12: Favre R, Bagarry-Liegey D, Jeanroy B, Pignon T, Meyer G, Carcassonne Y. Immunomodulation by NPT 15392 in cancer patients under chemotherapy. Adv Exp Med Biol. 1983;166:261-8. PubMed PMID: 6650281. 13: O'Neill BB, Ginsberg T, Hadden J. Immunopharmacology of the hypoxanthine containing compounds isoprinosine and NPT 15392. Prog Clin Biol Res. 1984;161:525-41. Review. PubMed PMID: 6207547. 14: Fudenberg HH, Whitten HD. Immunostimulation: synthetic and biological modulators of immunity. Annu Rev Pharmacol Toxicol. 1984;24:147-74. Review. PubMed PMID: 6203479. 15: Hadden JW, Keskiner Merriam L. Immunopharmacologic bases of immunotherapy. Clin Physiol Biochem. 1985;3(2-3):111-9. Review. PubMed PMID: 2408810. 16: Eichelberg D, Schmutzler W. [Pharmacological aspects of immunostimulants]. Immun Infekt. 1983 Jun;11(4):109-22. Review. German. PubMed PMID: 6085319. 17: Berendt MJ, Ives JL. Developmental status of synthetic immunomodulators. Year Immunol. 1985:193-201. Review. PubMed PMID: 2437723. 18: Wybran J. The immunopharmacology of synthetic immunomodulators. Prog Clin Biol Res. 1983;132E:95-103. PubMed PMID: 6196792. 19: Pfadenhauer EH, Bankert CS, Jensen J, Jones CE, Jenkins EE, McCloskey JA. Identification of the metabolites of erythro-9-(2-hydroxy-3-nonyl)hypoxanthine from laboratory animals. Drug Metab Dispos. 1984 May-Jun;12(3):280-4. PubMed PMID: 6145553. 20: Hadden JW. Chemically defined immunotherapeutic agents. Prog Clin Biol Res. 1983;132E:273-86. PubMed PMID: 6196787.

View History

Sch 24518

Sch 24518

BPH-676

BPH-676

Prospasmine

Prospasmine

GR-46611

GR-46611

Sulazuril

Sulazuril

Dermoglaucine

Dermoglaucine